Model Medicines is an AI-first biotechnology company that uses its GALILEO generative chemistry platform to design first-in-class small molecules against conserved biological choke points underlying disease. Its lead assets are MDL-001, a direct-acting broad-spectrum antiviral, and MDL-4102, a selective BRD4 inhibitor, with research spanning infectious disease, oncology and inflammation. Founded in 2019 by Daniel Haders II and Sean Russell, the San Diego company has advanced 15 drug candidates across more than 30 indications and is building a broad antiviral patent portfolio.
1
Round
1
Industry
5
Tags
Oct 21, 2026
Latest raise
Funding activity · 1 round
Oct 21, 2026
$5.1M
Series A
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
